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Abstract
Objectives: To perform a systematic review, and to verify and define deficiencies in literature data on drug policy and management of access to re-
imbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and Poland as a source of information intended to be used by govern-
ment authorities in the decision-making process.
Methods: A systematic review was conducted through database search of Medline, SCOPUS, Embase and Cochrane Library, supplemented by non-
systematic review. The quality of the identified literature was critically appraised. 
Results: Information necessary to develop a knowledge base was outline from 121 papers identified through database search. 0.83% of all publica-
tions were rated high in all of the assessed categories, i.e. were identified to represent high levels of consistency, coherence, strength and meth-
odological quality. 
Conclusions: In the policy decision-making process, concise recommendations based on validated data are more than needed. It is vital to rely on 
scientific evidence and avoid reports based on simple exchange of information or presenting single-source or unconfirmed data, including expert’s 
opinion.
Key words: data availability, decision-making process, methodology assessment, quality
Słowa kluczowe: dostępność danych, jakość, ocena metodologii, proces decyzyjny
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Introduction
The objective of this paper was to perform a systematic 
review, and to verify and define deficiencies in literature 
data on drug policy and access management to reimbursed 
medicinal products in the United Kingdom, Denmark, 
Germany, Italy and Poland. Found publications should 
serve as a source of information intended to be used in the 
decision-making process by government authorities who 
should rely on scientific evidence and avoid reports based 
on simple exchange of information between government 
institutions as well as reports and publications, based on 
single or random/unconfirmed sources of information. Ac-
cording to conversations with a number of officials from 
the Polish Ministry of Health and own conclusions from 
the review of official reports [1–5], we arrived at the hy-
pothesis that the proper methodology of systematic litera-
ture review and assessment of the quality of the identified 
papers and the obtained data is not so common as expected 
previously. As a result, this work is intended to investigate 
and outline the possible bias which could originate from 
using and relying on data sources other than those derived 
from proper scientific methodology for identifying lit-
erature data eligible to be included in official reports. Our 
hypothesis is mainly based on a common practice of in-
sufficient or missing description of methodology defining 
the inclusion criteria for publications quoted such reports 
[1–5]. Despite the fact that systematic review involving 
quality assessment of the literature data has been widely 
recognized as methodological standard, it is still uncom-
mon in institutional practice.
In order to estimate the extent to which data from 
poor-quality publications are in fact used, and the chance 
of finding high-quality article without employing the 
widely recognized methodology of systematic review 
and assessing literature data quality, we evaluated the 
quality of a large number of literature data addressing 
specific areas of drug policy and management of access 
to reimbursed medicinal products in the United Kingdom, 
Denmark, Germany, Italy and Poland, on the assumption 
that otherwise some biased conclusions can be arrived at.
This work was part of International Research Project 
on Financing Quality in Healthcare – InterQuality, Work 
Package 3, whose objective is to validate pharmaceutical 
benefit financing (pricing and reimbursement) models 
used in: 
1. Tax or social health insurance systems, relying main-
ly on official drug prices, government-regulated dis-
tribution mark-ups, and pharmaceutical care rewards.
2. Private or mixed health insurance systems, relying 
mainly on market forces and used in managed com-
petition framework to set drug prices, manage distri-
bution costs, and set pharmaceutical care incentives.
Methods
Work outline
Firstly, on the basis of our knowledge and multiple 
consultations with various experts, we prepared a list of 
issues and problematic questions to be answered during 
the data research. Secondly, in order to assess availability 
of data and collect the intended set of information, we 
performed a standard systematic review and developed 
a bibliography list of all relevant full-text papers included 
in the review, extracting the most important data into pre-
defined tables. On conclusion of the systematic review, 
it was concluded that some necessary information and 
data were still missing and therefore a “non-systematic 
review” was carried out to improve data availability and 
quality. The non-systematic review consisted of manual 
literature search, tracing the relevant references to select-
ed full texts, and consulting experts in the areas of inter-
est about other relevant papers they are familiar with. The 
collected information and data were extracted to the same 
pre-defined table used in the systematic review.
Finally, having collected all papers, the quality of 
various types of publications was assessed using three 
checklists which were considered relevant for the design 
of specific papers to avoid possible mistakes in the appli-
cation of checklists. In addition to quality assessment of 
publication designs, the actual value of the publications 
was scrutinised and the assessment results were entered 
in the tables. 
Figure 1 presents the workflow diagram.
Developing lists of issues and problematic questions
The first methodology used in the development of 
a list of relevant topics was the Focus Group Discussion 
(FGD) – the most popular qualitative technique demon-
strated to be valuable in many scientific and commercial 
applications, where confrontation and mutual stimulation 
of respondents is expected to deepen understanding of 
the subject discussed. FGD advantage is that it not only 
accumulates participants’ expertise, but it also can pro-
duce synergy between them: common understanding of 
the subject is created as group members start to stimulate 
and to enlighten each other, sharing their experience. On 
the other hand, the commonly recognized disadvantage 
of FGD is the “group effect” attributed to the natural 
pressures towards conformity.
The second methodology was Delphi Panel Method 
– “a structured method of eliciting expert judgment that 
is particularly useful as a tool to achieve consensus of 
opinion when the decisive factors are subjective”. Delphi 
procedure involves a series of interrogations in which 
anonymous responses of group members are submitted 
to the group for comment until consensus is reached. 
The WP3 research team, being a group experienced in 
the healthcare sector and representing a range of envi-
ronments and perspectives, acted as the expert panel and 
developed the list of relevant topics and questions based 
on the outcomes of FGDs and the Delphi panel. The list 
was validated by a group of experts from other partner 
countries at the InterQuality meeting in Catania on 25 
May 2012. The list was the basis for inclusion of publica-
tions as part of the systematic review.
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Methodology of systematic review
Systematic literature review was conducted through 
database search of Medline, SCOPUS, Embase and 
Cochrane Library. A search strategy (Table I and II) was 
established to identify the available literature data on top-
ics defined during FGDs and the Delphi panel. A number 
of synonyms was identified for each phrase. “Wild cards” 
were employed to broaden the search, including different 
forms of key words. Key words were combined using the 
Boolean system. The review involved specific limitations 
attributed to the need to make room for economic studies. 
The first step in selecting publications was the “title/
abstract screening”. The review was performed by eight 
members of the WP3 team. Inclusion criteria were as fol-
lows:
1.  Addressing one of the previously defined areas of 
interest (healthcare systems as a framework for drug 
policy, pricing and reimbursement, and co-payment).
2.  Description of problems from the system-wide and 
multiple-issue point of view.
To account for the economic studies, the inclusion 
criteria by PICOTS (population, intervention, compara-
tor, outcomes, time, setting) were implemented, save for 
some limitations:
• Population: any individuals or organizations receiv-
ing or providing the intervention/policy in the topic 
of our interest.
• Intervention: if relevant, initiatives to improve qual-
ity, equity, safety and efficiency of the intervention/
policy in the topic of our interest.
• Comparator: if relevant, of available, alternative ini-
tiative to those listed in the Intervention.
• Outcome: outcomes of interest in the framework of 
InterQuality Project: quality, costs, efficiency and 
equity in the framework of process, structure and 
outcome.
• Time: review was limited to years 2002–2012.
• Settings: Intervention/policy in areas of our interest 
(healthcare systems as a framework for drug policy, 
pricing and reimbursement, and co-payment).
RCTs were excluded.
On exclusion of irrelevant publications in the title/
abstract screening, the full-text review was performed. 
Publications unavailable in full text in English or Pol-
ish were also excluded. Each publication was reviewed 
by two reviewers to check if all the inclusion criteria 
were met. Where any disputes over the inclusion arose, 
the final decision was based on consensus. If the con-
sensus failed to be reached, the decision was made by 
the scientific coordinator of the review. Finally, complete 
bibliography lists of the identified full-text publications 
were prepared.
The most important data from the included papers 
were extracted into the predefined tables and short de-
scriptions were entered into tables for identification. At 
this point, the areas of insufficient data, inadequate infor-
mation content or deficiencies in any important data were 
identified for further research under the “non-systematic 
review”.
Methodology of manual search
An additional “hand-search” of literature was per-
formed. References were traced of full texts identified in 
the systematic review and included in the bibliography 
MS3 − work outline
assessment of 
information 
gathered
dening the areas
of inadequate
information content,
deciency or lack
of data needed
considering new
methodology
of collecting and
cempleting data
needed
preparation of the
list of adequate
issues and
problematic
questions
extracting the data
to pre-dened table
performing anon-
systematic review
(hand-searching)
discovering the areas
of pure data quality
and dening future
needs
validation of the list
at the WP3 meeting
in Catania
developing the
bibliographic list
of publications
extraction of the
data to previous pre-
dened table
assessment of the
overall information
and data gathered
planning the 
systematic review
performing the
systematic review
choosing relevant
and various quality
assessment checklists
assessment of the
quality of all papers
gathered from
systematic and non-
systematic reviews
Figure 1. Work outline diagram.
Source: Own elaboration.
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No Query
#1 generic OR nonproprietary OR “Drugs, Generic”[Mesh] 
#2 statins OR “Hydroxymethylglutaryl-CoA Reductase Inhibitors”[Mesh] OR simvastatin OR rosuvastatin OR atorvastatin 
#3 prescription OR substitution OR switching OR replacing OR “Drug Substitution”[Mesh] OR “preffered drug”
#4 #1 AND #2 AND #3
#5 innovative OR innovation
#6 medicine OR drug OR pharmac* 
#7 #5 AND #6
#8 “new entity” OR “new drug” 
#9 #7 OR #8
#10 “e-prescribing” OR „electronic prescribing” OR “e-prescription” OR “electronic prescription” OR “electronic medical record” OR 
“computerized medical record” OR “electronic health record” OR “computerized health record” OR “electronic drug monitoring” 
OR “computerized drug monitoring” OR “online adjudication” OR “pharmacy claims” OR “DUR” OR “drug utilization review” 
OR “PBM” OR “pharmacy benefit management” 
#11 transparency OR access OR accessibility OR affordability 
#12 #6 AND #11
#13 “personalised medicine” OR “personalized medicine” OR “targeted therapy” 
#14 #4 OR #9 OR #10 OR #12 OR #13
#15 “market share” OR price OR incentives OR “patient satisfaction” OR cost OR spendings OR (financing AND (model OR system)) 
OR (principal AND agent) OR agent OR distribution OR competitiveness OR formulary OR trend OR “cost driver” OR “patient 
satisfaction” OR reimbursement 
#16 Poland OR “United Kingdom” OR “UK” OR Germany OR Italy OR Denmark OR “United States” OR “US” 
#17 #14 AND #15 AND #16
#18 randomised OR randomized OR “double-blind” OR “cross-over” OR crossover 
#19 #17 NOT #18
Table I. Search strategy for PubMed.
Source: Own elaboration.
Collection Search Strategy for SCOPUS
Copayment ((((TITLE-ABS-KEY-AUTH(coinsurance))OR(TITLE-ABS-KEY-AUTH(copayment))OR(TITLE-ABS-
-KEY-AUTH(deductible))OR(TITLE-ABS-KEY-AUTH(consumerdirectedhealthplan))OR(TITLE-ABS-
-KEY-AUTH(healthsavingsaccount))OR(TITLE-ABS-KEY-AUTH(costsharing))OR(TITLE-ABS-KEY-
-AUTH(referencepricing))))AND((TITLE-ABS-KEY-AUTH(pharmaceutical*))OR(TITLE-ABS-KEY-AUTH(medicine*))
OR(TITLE-ABS-KEY-AUTH(drug*))))AND(((TITLE-ABS-KEY-AUTH(access))OR(TITLE-ABS-KEY-
-AUTH(quality))OR(TITLE-ABS-KEY-AUTH(equity))OR(TITLE-ABS-KEY-AUTH(efficiency))OR(TITLE-ABS-
-KEY-AUTH(healthoutcome))OR(TITLE-ABS-KEY-AUTH(effectiveness))OR(TITLE-ABS-KEY-AUTH(utilization)))
OR(TITLE-ABS-KEY-AUTH(expenditure))OR(TITLE-ABS-KEY-AUTH(spending))OR(TITLE-ABS-KEY-
-AUTH(payment*)))AND(LIMIT-TO(SUBJAREA,”MEDI”)ORLIMIT-TO(SUBJAREA,”HEAL”)ORLIMIT-
-TO(SUBJAREA,”ECON”))AND(LIMIT-TO(LANGUAGE,”English”))
Distribution (drug* OR medicine* OR generic OR pharmac*) AND (distribution OR deliver* OR delivery OR sale) AND (wholesale* 
OR intermediating distributors OR chemists OR drugstore OR pharmacy OR Pharmaceutical compan* OR producer* OR 
manufacturer*) AND ((margin* OR mark-up*) OR (discount* OR bonus* OR rebat* OR subsid* OR fee* OR marketing 
service*) OR (price* OR net selling OR net purchase OR retail OR wholesale) OR (direct OR indirect) OR (incentives) 
OR (PBM OR pharmacy benefit management) OR (annual amount of sale OR earnings OR profits OR benefits OR market 
share) OR (online market) OR (availability OR equity OR access OR accessibility OR affordability) OR (parallel import) 
OR (law OR regulations) OR (adherence OR compliance) OR (financing AND model* OR system* OR scheme*))
Table II. Search strategy for SCOPUS.
Source: Own elaboration.
list of publications addressing the applicable areas of in-
terests. Papers found to be particularly appropriate were 
analyzed and the authors of these papers were tracked to 
include additional relevant papers, if any. Other essential 
papers known to experts were also included. The manual 
search was performed by individuals responsible for the 
respective area of interest.
The identified papers were added to the bibliography; 
the most important data were extracted to pre-defined ta-
bles and short descriptions were added. 
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Next, as in the previous step, all information collected 
so far was assessed from the factual point of view. If any 
particular area of interest was considered to be covered 
by insufficient or inadequate data, it was qualified for 
further research, as was the case in the systematic review.
Methodology of quality assessment
The next step was the quality assessment of the iden-
tified publications and adjustment of robustness of ex-
tracted data to the quality of source publications.
A bibliography list was compiled from both reviews. 
Publications included therein represented a broad spec-
trum of research design. It also included papers without 
any specific design which nevertheless contained some 
useful information. The area of research – covering the 
overall healthcare systems – made the quality assessment 
particularly difficult as it included descriptions of many 
types and outcomes of possible and existing interventions 
which have never been appropriately and comprehensive-
ly identified, described and categorized in the literature.
According to expert opinion, we chose to assess the 
quality of the actual contents of the identified publica-
tions (with economic papers prevailing) on the basis of 
methodology described by West et al. [6]. This tool ap-
peared to be appropriate for the critical appraisal of the 
contents of all identified literature, including health eco-
nomics literature data, and all included publications were 
assessed accordingly. 
The critical appraisal of all collected publications was 
based on three aspects found by West et al. consistency, 
coherence and strength. 
• Consistency – the extent to which diverse approaches, 
such as different study designs or populations, for 
studying a relationship or link between a factor and 
an outcome will yield similar conclusions.
• Coherence – whether the cause-and-effect conclu-
sions conflict with what is known of the reality.
• Strength – the size of estimated effect.
Each of these categories was graded as high, moder-
ate or low. 
The above mentioned methodology proved to be in-
sufficient as it did not include any assessment options 
of design-specific sources of bias, selected outcomes or 
selected method of obtaining outcomes (such as statis-
tics, etc.). As there is no ready-to-use tool to critically 
appraise all types of publications, and in order to avoid 
the bias of inappropriate use of a tool designed to assess 
quality of one type of research to the other, composite 
criteria were selected for the quality assessment.
The identified publications were classified into three 
main categories: 
1. Systematic reviews and meta-analyses.
2. Trials and studies which could be described as ob-
servational studies in terms of their design, provided 
they were not in a whole health care system setting.
3. Literature polemics, descriptions of healthcare sys-
tems and results of conducted non-systematic litera-
ture reviews.
We chose to use a tool created for the assessment of 
methodological quality of systematic reviews – com-
bined PRISMA and MOOSE checklists developed by 
Liberati et al. [7] and Stroup et al. [8, 9] for category 
1 of the identified publications (systematic reviews and 
meta-analyses). To make it similar to the other three cat-
egories (consistency, coherence and strength described 
by West et al. [6]) of already performed assessment, we 
chose three-level evaluation as well, and we reported the 
results broken down into quality levels: low, medium 
and high. Classification was made by competent experts 
and was susceptible to bias as it was subjective because 
PRISMA and MOOSE checklists do not summarize into 
a numeric score. For category 2 of the identified publica-
tions, the STROBE checklist (Vandenbroucke et al. [10]) 
(http://www.strobe-statement.org) was chosen and the 
results were also reported as low, medium and high qual-
ity. Likewise, the STROBE checklist did not provide any 
summary score and the classification made by competent 
experts was therefore subjective.
The quality was not possible to be critically appraised 
in all identified papers. The methodology of category 3 
publications in our categorization list was highly individ-
ual and therefore it was not possible to assess its quality. 
All categories were assessed by two reviewers inde-
pendently, who were responsible for each relevant area of 
interest as the expert’s knowledge of literature on a par-
ticular topic was an essential component of the assess-
ment. The results of this evaluation were listed into the 
quality assessment table (Table IV).
The results of systematic and non-systematic review
The final date of performing the review was 28th Oc-
tober 2012, which is considered the cut-off date.
As previously assumed, the identified publications 
were reviewed and divided to collect separate sets of 
data relevant to the defined areas of interest. The system-
atic review produced the total number of 14 723 hits. On 
screening the titles or abstracts from the databases, 14 
489 publications were excluded from the analysis. The 
remaining 234 abstracts were included into the full-text 
analysis. Finally, 145 full-text articles were excluded and 
89 full-text publications were included in the bibliogra-
phy collection.
32 full-text publications and articles identified in the 
non-systematic review were added to the bibliography 
collection.
To sum up, the two types of reviews identified 89 
and 32 full-text publications from systematic and non-
systematic reviews, respectively, and the total number 
of 121 texts was finally included in the analysis [1–5], 
[11–124]. A complete bibliographic list of full-text publi-
cations was prepared. The results of the overall literature 
review are presented in Figure 2.
The results of the literature review broken down into 
specific areas of interests/collections are listed in Ta-
ble III.
In accordance with the search strategy, out of 14 723 
abstracts found in Medline, Embase, Cochrane Library 
and SCOPUS, the number of included abstracts (listed 
in brackets) for the relevant collections were as follows: 
Access and Copayment (196), Health Systems (38).
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Figure 2. Results of literature review.
Source: Own elaboration.
Excluded
title/abstract
14 489
Included
title/abstract
234
References/
other sources
32
Finally included
121
Excluded 
full text
145
Included 
full text
89
Medical databases
14 723
Collection
Number of included 
abstracts (Systematic 
Review)
Number of included full 
texts (Systematic Review)
Number of included full 
texts Reference/other 
sources (Manual search)
Final number of included 
full texts
Access &  
Co-payment
196 72 5 77
Health Systems 38 17 27 44
Summary 234 89 32 121
Table III. The results of the review.
Source: Own elaboration.
Once full texts were reviewed, the number of in-
cluded articles and publications decreased to: Access and 
Copayment (72), Health Systems (17).
The non-systematic review revealed a number of rel-
evant publications which the systematic review did not 
found. Thanks to the non-systematic review the number 
of added publications was as follows: Access and Copay-
ment (5), Health Systems (27).
Both types of reviews produced the following num-
ber of publications: Access and Copayment (77) [1, 3, 5, 
11–84], Health Systems (44) [1–4, 85–124].
The results of quality assessment of the identified publications 
(4-dimensional analysis – consistency, coherence, strength 
assessment and quality, if appropriate)
The overall number of publications qualified for fur-
ther analyses was 121; all have been assessed for quality.
All collected publications were assessed in terms of 
three parameters (consistency, coherence and strength). 
25.62% of publications [1, 3, 5, 14, 15, 17, 18, 25, 29, 30, 
32–34, 37, 38, 40, 46, 50, 55, 56, 59, 67, 68, 71–73, 75, 
77, 78] represented high levels of consistency. 30.58% 
of publications represented high levels of coherence [1, 
3, 5, 14, 15, 17, 18, 21, 23–25, 27, 29, 30, 32, 33, 37, 38, 
40, 44, 46, 50, 55, 56, 59, 63, 67, 68, 71, 73, 75, 77, 78], 
whereas 15.70% of publications revealed high levels of 
strength [1, 3, 5, 14, 21, 25, 44, 46, 50, 55, 64, 69, 70, 98, 
104, 105, 114, 122].
51 of all included publications (42.15%) were classi-
fied as meta-analyses, literature reviews and studies and 
were to be assessed in accordance with the appropriate 
checklist (PRISMA, MOOSE or STROBE). As a result, 
33.33% of publications represented high levels of quality 
[18, 25, 30, 33, 37, 41, 42, 44, 52, 56, 63, 68, 72, 73, 77, 
83, 84]. 47.06% and 19.61% of publications represented 
medium and low quality levels, respectively. Only 0.83% 
of publications were graded high in all four parameters 
(four-dimensional evaluation: consistency, coherence, 
strength, and quality) [25]. The results of the quality as-
sessment are presented in Table IV.
Discussion
Only 0.83% of the identified publications addressing 
the analyzed areas of drug policy and access management 
to reimbursed medicinal products in the United King-
dom, Denmark, Germany, Italy and Poland were found to 
represented high levels of quality in the four-dimensional 
evaluation. This is the reason why random assortment 
of scientific literature may involve a high probability 
of identifying and using publications of poor quality or 
containing data which do not reflect the reality. It should 
be underlined that, under scientific circumstances, an ac-
curate and reliable picture of reality can be only produced 
from data presented in all a variety of different publica-
tions instead of a single source of information. The meth-
odology of using two reviewers combined with quality 
assessment of the identified publications allows to select 
articles presenting high quality data. In the light of the 
results presented in this paper, a scientific approach to 
the literature selection should be recommended whenever 
possible. Moreover, from the point of view of the public 
officials, it is important to attempt to improve the pub-
lication assortment by relying on widely acknowledged 
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Collection
Consistency Coherence Strength Quality Used checklist No of  
publications
L M H L M H L M H L M H A N/A
Access and Co-payment 0 47 30 1 40 36 1 63 13 9 16 17 42 35 77
Health Systems 3 40 1 2 41 1 10 28 6 1 8 0 9 35 44
Summary 3 87 31 3 81 37 11 91 19 10 24 17 51 70 121
Legend: L – low, M – medium, H – high, A – applicable (one of the checklists used: PRISMA, MOOSE or STROBE), N/A – not 
applicable
Table IV. The quality assessment results – summary.
Source: Own elaboration.
rules of data selection and quality assessment. Addition-
ally, it is highly important to spend sufficient amount of 
time on the review process in order to properly conduct 
the systematic literature review and to avoid mistakes 
that could result in a scientific bias.
The assessment of literature review presented in this 
paper involves specific limitations. It covered papers 
identified with the use of the adopted strategy instead 
of data derived from governmental reports. Although it 
was attempted to cover a broad spectrum of possible 
areas of interest, we were able to target a slightly differ-
ent literature than the one used by the authors of such 
reports. Our own search strategy was used because none 
of such strategies was revealed in any of the reports in 
question. It is also possible that the authors of the re-
ports could have been familiar with particular sources 
of information and deliberately did not search for 
them while preparing the reports. Therefore, it cannot 
be ruled out that the actual percentage of high-quality 
sources and data is different from the one identified in 
this paper. However, bias is likely to be produced by 
relying solely on sources known to the authors, with no 
account taken of their quality, or without updating and 
screening for new information.
The methodology of quality assessment of economic 
publications developed by West et al. [6] did not include 
any assessment of design-specific bias. As there is no tool 
appropriate to critically appraise all types of publications, 
we chose to add one more category to the quality assess-
ment of identified publications. After grouping papers 
according to their design, we chose widely accepted, but 
not summarizing into a numeric scores checklists (PRIS-
MA, MOOSE and STROBE) for the quality assessment 
of each group of found publications. The potential limita-
tion of this assessment was that outcome was subjective 
and susceptible to bias.
As we mentioned before, the quality was not possible 
to be critically appraised in all identified papers. There 
also have been papers without any specific design, but 
containing some information useful for our objectives 
and considered important as being unique source of spe-
cific detailed information. We did not assess at all the 
quality of their design and that was the next possible 
limitation of our work.
Conclusions
A large number of publications strictly addressing the 
defined areas of interest were identified and included in 
this analysis of availability and quality of data. 42.15% of 
them, to a large part consisting of studies, meta-analyses 
and reviews, were identified as relevant in terms of qual-
ity assessment. 33.33%, 47.06% and 19.61% of the iden-
tified publications were classified as high-, medium- and 
low-quality publications, respectively. Moreover, data on 
some areas of interest were found to be scarce or miss-
ing. There were no comparable analyses found and no 
relevant reliable data available. To improve the quality 
and reliability of information available to decision mak-
ers, multiple sources should be used, identified by means 
of the broadly accepted methodology of searching for pa-
pers in all available databases and assessing the quality of 
the identified materials by the best and the most accepted 
methods, at least to the extent possible. 
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